48 patents currently held
6 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Dec 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
20
Ending by 2030
Dec 2026
Next term end
25
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Aug 2027 · High confidence
Also notable
Ends Nov 2032 · High confidence
Also notable
Ends Apr 2029 · High confidence
Combinations and Modes of Administration of Therapeutic Agents and Combination Therapy
US 8,735,394
Cited by 159 later US patents, top 5% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2027.
Nanoparticle Comprising Rapamycin and Albumin as Anticancer Agent
US 8,911,786
Cited by 101 later US patents, top 5% of utility patents granted in 2014 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2032.
Compositions and Methods for Preparation of Poorly Water Soluble Drugs with Increased Stability
US 8,034,765
The most cited patent in this portfolio, cited by 174 later US patents, top 5% of utility patents granted in 2011 in our data. Protection runs to 2029.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 25, 2026The maintenance fee for Methods of Treating Pancreatic Cancer (US 10,328,031) comes due Dec 25, 2026. Unpaid by Jun 25, 2027, it lapses early.
- 1 fee due Jan 28, 2027The maintenance fee for Use of 2 Anti-Sparc Antibodies to Predict Response to Chemotherapy for Pancreatic Adenocarcinoma (US 9,091,697) comes due Jan 28, 2027. Unpaid by Jul 28, 2027, it lapses early.
- 1 fee due Mar 17, 2027The maintenance fee for Methods of Treating Bladder Cancer (US 10,413,531) comes due Mar 17, 2027. Unpaid by Sep 17, 2027, it lapses early.
- 1 fee due Apr 6, 2027The maintenance fee for Methods of Treating Melanoma (US 9,149,455) comes due Apr 6, 2027. Unpaid by Oct 6, 2027, it lapses early.
- 1 fee due Jul 7, 2027The maintenance fee for Methods of Assessing Suitability of Use of Pharmaceutical Compositions of Albumin and Paclitaxel (US 10,527,604) comes due Jul 7, 2027. Unpaid by Jan 7, 2028, it lapses early.
- 1 fee due Aug 11, 2027The maintenance fee for Use of Polymeric Excipients for Lyophilization or Freezing of Particles (US 10,555,912) comes due Aug 11, 2027. Unpaid by Feb 11, 2028, it lapses early.
- 1 fee due Sep 29, 2027The maintenance fee for Sparc Binding Scfvs (US 9,295,733) comes due Sep 29, 2027. Unpaid by Mar 29, 2028, it lapses early.
- 3 fees due Oct 2 to 19, 2027 · next Oct 2
Recent changes
- 4 terms have ended since Aug 16, 2026
What they patent
The 5 largest of its 25 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Sparc Binding Scfvs | 5 in force | to Dec 2030 |
| Breast Cancer Therapy Based on Hormone Receptor Status with Nanoparticles Comprising Taxane | 4 in force | to Dec 2027 |
| Methods of Assessing Suitability of Use of Pharmaceutical Compositions of Albumin and Poorly Water Soluble Drug | 3 in force | to Mar 2036 |
| Methods of Treating Pancreatic Cancer | 3 in force | to Jan 2034 |
| Use of Polymeric Excipients for Lyophilization or Freezing of Particles | 3 in force | to Dec 2032 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,420,603 | Sparc and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 8,946,169 | Sparc and Methods of Use Thereof In force · Medium confidence | In force | Medium confidence | |
| US 8,735,394 | Combinations and Modes of Administration of Therapeutic Agents and Combination Therapy In force · High confidence | In force | High confidence | |
| US 8,999,396 | Breast Cancer Therapy Based on Hormone Receptor Status with Nanoparticles Comprising Taxane In force · High confidence | In force | High confidence | |
| US 9,675,578 | Breast Cancer Therapy Based on Hormone Receptor Status with Nanoparticles Comprising Taxane In force · High confidence | In force | High confidence | |
| US 9,724,323 | Breast Cancer Therapy Based on Hormone Receptor Status with Nanoparticles Comprising Taxane In force · High confidence | In force | High confidence | |
| US 10,682,420 | Breast Cancer Therapy Based on Hormone Receptor Status with Nanoparticles Comprising Taxane In force · High confidence | In force | High confidence | |
| US 8,415,304 | Sparc and Methods of Use Thereof In force · High confidence | In force | High confidence | |
| US 8,034,765 | Compositions and Methods for Preparation of Poorly Water Soluble Drugs with Increased Stability In force · High confidence | In force | High confidence | |
| US 8,821,836 | Sparc Binding Peptides and Uses Thereof In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 48: 6 patents in force now held by others · 34 patents ended · 5 applications pending · 151 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.